Medicine Responds to Addiction: Implementing Physician Training

Sponsored by
The Addiction Medicine Foundation
in partnership with
National Institute on Alcohol Abuse and Alcoholism,
National Institute on Drug Abuse,
Substance Abuse and Mental Health Services Administration

Speakers and Introducers

The Addiction Medicine Foundation
National Institute on Drug Abuse
National Institute on Alcohol Abuse and Alcoholism
Substance Abuse and Mental Health Services Administration

Tuesday, January 30, 2018
June S. Sivilli, M.A.

Division Chief
Public Health & Public Safety
Office of National Drug Control Policy (ONDCP)
jsivilli@ondcp.eop.gov

June S. Sivilli serves as the Division Chief for Public Health and Public Safety, in the Office of National Drug Control Policy, Executive Office of the President. In this role, Ms. Sivilli and her staff develop and advance the agencies public health and public safety policies that comport with policies integrating substance use disorder services into mainstream health. She works on related workforce issues, and integrating the use of medication assisted treatment in correctional settings within drug policy and criminal justice efforts. Ms. Sivilli has led national efforts in raising awareness of Addiction Medicine as a new medical specialty, and led the coordination and implementation of the practice of Screening and Brief Intervention (SBI) in the academic and health fields. She conducted international policy work for 14 years on drug policy issues representing the US at the United Nations and the Organization of American States.

Ms. Sivilli joined ONDCP's Research Office in 1996. Prior to joining ONDCP, Ms. Sivilli conducted research in the private sector. Ms. Sivilli's training is in Sociology from George Washington University (MA 1986), and Stony Brook University (BA 1982).

The Office of National Drug Control Policy (ONDCP)
The Office of National Drug Control Policy (ONDCP) works to reduce drug use and its consequences by leading and coordinating the development, implementation, and assessment of U.S. drug policy. In addition to its vital ongoing work, ONDCP provided administrative and financial support to the President’s Commission on Combating Drug Addiction and the Opioid Crisis, established by Executive Order on March 29, 2017 by President Donald J. Trump.

A component of the Executive Office of the President, ONDCP was created by the Anti-Drug Abuse Act of 1988. The ONDCP Director is the principal advisor to the President on drug control issues. ONDCP coordinates the drug control activities and related funding of 16 Federal Departments and Agencies. Each year, ONDCP produces the annual National Drug Control Strategy, which outlines Administration efforts for the Nation to reduce illicit drug use, manufacturing and trafficking; drug-related crime and violence; and drug-related health consequences. ONDCP also leads the development of the consolidated Federal drug control budget, which is published annually in the National Drug Control Strategy: Budget and Performance Summary. The FY 2018 budget for drug control funding is $27.8 billion.
George F. Koob, Ph.D.

Director
National Institute on Alcohol Abuse and Alcoholism (NIAAA)/NIH

Dr. George Koob, an internationally-recognized expert on alcohol and stress, and the neurobiology of alcohol and drug addiction, began his tenure as Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) on January 27, 2014. As NIAAA Director, Dr. Koob oversees a wide range of alcohol-related research, including genetics, neuroscience, epidemiology, prevention, and treatment.

Even before beginning as NIAAA Director, Dr. Koob had a longstanding relationship with the Institute. Throughout his career, he received funding from NIAAA and other NIH institutes for many significant research projects. Importantly, he also led a 10-year, NIAAA-funded, multi-institutional consortium dedicated to identifying the molecular basis of alcoholism.

Dr. Koob received his Ph.D. in Behavioral Physiology from Johns Hopkins University in 1972. He spent most of his career at the Scripps Research Institute, where he served as the Director of the Alcohol Research Center, and as Professor and Chair of the Scripps' Committee on the Neurobiology of Addictive Disorders. Early in his career, he served as a researcher in the Department of Neurophysiology at the Walter Reed Army Institute of Research and in the Arthur Vining Davis Center for Behavioral Neurobiology at the Salk Institute for Biological Studies. He was a post-doctoral fellow in the Department of Experimental Psychology at the University of Cambridge.

Dr. Koob began his career studying the neurobiology of emotion, including how the brain processes reward and stress. His contributions advanced our understanding of the anatomical connections of emotional systems and the neurochemistry of emotional function. This background led to investigations into why certain alcohol drinkers transition to addiction while others do not, and how the brain and body respond to alcohol consumption.

Dr. Koob’s work has significantly broadened our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and other drugs of abuse, and of the neuroadaptations of the reward and stress neurocircuits that lead to addiction. In addition, he has validated key animal models for addiction associated with alcohol and drugs and identified the major role that brain stress systems play in the development of addiction. Dr. Koob is the author of more than 650 peer-reviewed scientific papers, and the co-author of The Neurobiology of Addiction, a comprehensive review of the most critical neurobiology of addiction research conducted over the past 50 years.

Dr. Koob is the recipient of many prestigious honors and awards, including the Daniel Efron Award for excellence in research and Axelrod Mentorship Award from the American College of Neuropsychopharmacology, the Distinguished Investigator and Marlatt Mentorship Awards from the Research Society on Alcoholism, the Mark Keller Award from NIAAA, and the Neuronal Plasticity Prize of the Foundation Ipsen.
Nora D. Volkow, M.D., became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health in May 2003. NIDA supports most of the world’s research on the health aspects of drug abuse and addiction.

Dr. Volkow’s work has been instrumental in demonstrating that drug addiction is a disease of the human brain. As a research psychiatrist and scientist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic effects and addictive properties of abusable drugs. Her studies have documented changes in the dopamine system affecting, among others, the functions of frontal brain regions involved with motivation, drive, and pleasure in addiction. She has also made important contributions to the neurobiology of obesity, ADHD, and aging.

Dr. Volkow was born in Mexico, attended the Modern American School, and earned her medical degree from the National University of Mexico in Mexico City, where she received the Robins award for best medical student of her generation. Her psychiatric residency was at New York University, where she earned the Laughlin Fellowship Award as one of the 10 Outstanding Psychiatric Residents in the USA.

Dr. Volkow spent most of her professional career at the Department of Energy’s Brookhaven National Laboratory (BNL) in Upton, New York, where she held several leadership positions including Director of Nuclear Medicine, Chairman of the Medical Department, and Associate Director for Life Sciences. In addition, Dr. Volkow was a Professor in the Department of Psychiatry and Associate Dean of the Medical School at the State University of New York (SUNY)-Stony Brook.

Dr. Volkow has published more than 680 peer-reviewed articles and written more than 100 book chapters and non-peer-reviewed manuscripts, and has also edited four books on neuroimaging for mental and addictive disorders.

During her professional career, Dr. Volkow has been the recipient of multiple awards. In 2013, she was a Samuel J. Heyman Service to America Medal (Sammies) finalist and was inducted into the Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) Hall of Fame. She was elected to membership in the Institute of Medicine in the National Academy of Sciences, received the International Prize from the French Institute of Health and Medical Research for her pioneering work in brain imaging and addiction science, and was awarded the Carnegie Prize in Mind and Brain Sciences from Carnegie Mellon University. She has been named one of Time magazine’s “Top 100 People Who Shape Our World”, “One of the 20 People to Watch” by Newsweek magazine, Washingtonian magazine’s “100 Most Powerful Women” in both 2015 and 2017, "Innovator of the Year" by U.S. News & World Report, and one of "34 Leaders Who Are Changing Health Care" by Fortune magazine. Dr. Volkow was the subject of a 2012 profile piece by CBS’s 60 Minutes and was a featured speaker at TEDMED 2014.
Dr. Everett is the Chief Medical Officer at SAMHSA. She is also the Director of the Office of Chief Medical Officers (OCMO). The OCMO is strategically positioned within SAMHSA to facilitate the development of policy, practice and programs that comport with best practices and current trends in contemporary health care. Dr. Everett comes to SAMHSA with long term experience in the delivery and leadership of psychiatric services.

Prior to her arrival at SAMHSA, she served as the Section Chief of The Johns Hopkins Bayview Community and General Psychiatry in Baltimore, Maryland. She was on the faculty of the Johns Hopkins School of Medicine and the Bloomberg School of Public Health. At Hopkins, she directed 22 community psychiatry programs that provide a range of services to individuals from preschool age to older adults and through a range of programs that include intensive acute services as well as recovery support services for persons with Serious Mental Illnesses. More recently at Hopkins, she has been involved with the leadership of health system behavioral health integration into accountable care structures. Earlier in her career, Dr. Everett served as the Senior Medical Advisor to the Substance Abuse and Mental Health Services Administration. There she worked on the promotion of access to quality services and access to medications in the Medicare prescription drug benefit. From 1999 to 2003 she served as the Inspector General to the Office of the Governor in the Department of Mental Health in Virginia. During this time she completed over 80 inspections of Institutions operated and licensed to provide mental health services in Virginia. She received the Patrick Henry award for outspoken advocacy.

Dr. Everett has served on the National Institute on Drug Abuse, National Advisory Council. She is active in several professional organizations including the American Psychiatric Association where she has received a commendation for her work in healthcare reform. She is a past president of the Maryland Psychiatric Society and the American Association of Community Psychiatrists. She has been engaged in a number of international projects which have included consultation with the Ministries of Health, Department of Mental Health in Iraq and Afghanistan on the implementation of mental health services in these countries.
Dr. Murray is Director of the Global Alcohol Research Program, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health. Dr. Murray directs NIAAA’s efforts in international research collaboration spanning each of the Institute’s priorities in biomedical, epidemiological, prevention and treatment research. This includes serving on U.S. Science and Technology Committees, NIH and government wide initiatives in global health, and representing NIAAA to multilateral organizations such as the World Health Organization, the Organization for Economic Cooperation and Development and National Academies of Science committees. She is primarily responsible for facilitating collaborative relationships at the individual institute and scientist level. Dr. Murray is a member of the Institute of Medicine’s Forum on Global Violence Prevention.

Since 2014, Dr. Murray has represented NIAAA on the Coordinating Committee for Collaborative Research on Addiction at the NIH, known as CRAN. The collaboration includes the National Institute on Drug Abuse and the National Cancer Institute. An important activity of CRAN is the large NIH Adolescent Brain and Cognitive Development Study, known as the ABCD study. This initiative is a longitudinal study of 11,500 children being followed from age 9-10 for 10 years to look at how exposure to substances of abuse and other environmental and social factors affect brain development. Dr. Murray serves on the Operations Group of the ABCD study and the Bioethics and Medical Oversight Committee for the study.

Dr. Murray also serves as the scientific staff collaborator on a large international multi-site Randomized Controlled Trial of the health effects of moderate drinking, developed as a partnership among NIAAA, the National Institute on Aging, the National Institute on Neurological Diseases and Stroke, Harvard/Beth Israel Deaconess Medical Center and the Foundation for the NIH.

Dr. Murray is also responsible for the Institute’s research translation initiatives in health professions education. She is co-author of A Medical Education Model for the Prevention and Treatment of Alcohol-Use Disorders, a twenty module curriculum and faculty development course for medical school faculty in the primary care specialties. The model has been translated into five languages and implemented in eight countries. She led the development of a model curriculum for social work educators, A Social Work Education Model for the Prevention and Treatment of Alcohol Use Disorders that is currently being disseminated and is also involved in a similar work in nursing education.

She has published in the areas of ethics in research on children and adolescents, Fetal Alcohol Spectrum Disorders, health effects of moderate drinking, screening and brief intervention for alcohol use disorders in primary health care settings, evaluation of international faculty development programs, and homelessness and alcohol and drug problems.

Dr. Murray received a BA degree in English from St. Mary’s College of Maryland, a public honors college. She holds PHD and MSW degrees in social policy from Catholic University in Washington, DC and certificates in epidemiology and biostatistics from Johns Hopkins University School of Public Health.

Dr. Murray served as adjunct faculty in the graduate Social Work programs at the Catholic University of America and Howard University. She is currently leading a course in Alcohol Across the Life Span at the Foundation for Advanced Education in the Sciences.
Ms. Corbin leads NIDAMED, the Institute’s clinician outreach program. In this role, Ms. Corbin works with national clinician organizations and federal partners to ensure NIDA’s science based information on drug use and addiction is integrated into medical education and clinical practice both in private clinics and in community-based settings.

Prior to NIDA, Ms. Corbin spent 14 years at HRSA, coordinating communications and recruitment efforts for the National Health Service Corps, a long standing federal HHS program that bring primary care clinicians to the most underserved communities in the Nation. In addition to her HHS career, Michelle has 12 years of legislative and membership marketing experience from two national health care provider Associations, the American Dental Association and the Society of General Internal Medicine, respectively.
Doug Tipperman is the Tobacco Policy Liaison for the Substance Abuse and Mental Health Services Administration (SAMHSA). He coordinates SAMHSA’s Tobacco-Free Recovery efforts, which focus on reducing tobacco use by persons with mental and/or substance use disorders.

In addition, he serves on the U.S. Department of Health and Human Services’ Tobacco Control Steering Committee chaired by the Surgeon General. Before his federal government service, he worked extensively at the state and local level to promote public policies that reduce tobacco use.

He has helped lead several successful policy change efforts including Maryland’s Clean Indoor Air Law, which succeeded in making all Maryland restaurants and bars smoke-free.
Dr. Christina Mikosz is a Medical Officer on the Opioid Overdose Health Systems team in the Division of Unintentional Injury Prevention at the Centers for Disease Control and Prevention.

In her current role, Dr. Mikosz leads efforts related to the implementation of the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain particularly around clinician training and education around safer opioid prescribing practices. She also provides technical expertise to states on Guideline-concordant care to support ongoing overdose prevention work, among other activities.

Prior to her current position at CDC, Dr. Mikosz worked in two different county public health departments in California, where she spearheaded efforts to study and improve the quality of healthcare service delivery. She completed internship and residency in Internal Medicine at the University of California – San Francisco, later joining the hospital medicine faculty there, and is Board Certified in Internal Medicine.

She received her BA at Northwestern University, her MPH from the University of Illinois at Chicago, her medical degree at Rush Medical College, and also previously served as an Epidemic Intelligence Service (EIS) Officer with the CDC.
Patrick G. O’Connor, M.D., M.P.H.

Chief of General Internal Medicine
Yale School of Medicine
Director, The Addiction Medicine Foundation
patrick.oconnor@yale.edu

Dr. Patrick O’Connor is a Dan Adams and Amanda Adams Professor of General Medicine and Chief of General Internal Medicine at Yale University School of Medicine and Yale-New Haven Hospital in New Haven, Connecticut. Dr. O’Connor came to Yale as a fellow in the Robert Wood Johnson Clinical Scholars Program during which time he also received a M.P.H. from the Yale School of Public Health. As Chief of General Internal Medicine at Yale he led several new initiatives in patient care, education, and research and has overseen a 3-fold expansion in the size of the faculty and 10-fold increase in research funding.

Dr. O’Connor’s research has focused on the interface between primary care and addiction medicine. Specific topics within his research area have included: 1) the integration of primary care and substance use disorder treatment services, 2) strategies for primary care-based opioid detoxification and opioid maintenance for the treatment of opioid use disorder, 3) strategies for managing unhealthy alcohol use and alcohol use disorder in primary care settings, 4) medical education about addiction, and 5) addiction health policy. He has written over 200 scientific papers on these topics and his work has been published in leading medical journals including The New England Journal of Medicine, and JAMA. Among these publications is the first randomized trial of buprenorphine in primary care. More recently, he served as an author on Facing Addiction in America. The Surgeon General’s Report on Alcohol, Drugs, and Health. His research has been funded through the receipt of numerous grants from the NIH, other federal agencies, and from foundations. He has also collaborated with federal agencies such as The White House Office on Drug Control Policy and with addiction-focused organizations in academia and the private sector.
Dr. Albanese is an Affiliations Officer with the VA Office of Academic Affiliations. He is also a Clinical Professor of Medicine and Psychiatry at the UC Davis School of Medicine. He became a member of ASAM while still in training at St. Lukes-Roosevelt Hospital in New York, and became a certified addictionist in 1991. He completed his hepatology fellowship at the University of Miami in 1992 and practiced gastroenterology, hepatology, and addiction medicine in Miami for the next 10 years.

In 2001, he moved to Sacramento California and continued his work at the VA. In 2016, he accepted a national position as an Affiliations Officer with the VA Office of Academic Affiliations. He continues clinical and MRO work at the Northern California VA. His clinical research interests have been in the medical aspects of opioid and alcohol abuse, and intestinal changes associated with HIV infection.

Dr. Albanese was elected to a Director-at-Large position on the CSAM Executive Council in 2013, and is currently the CSAM president-elect. In 2014 he was elected to the Director-at-Large position on the ASAM Executive Board, served on the Addiction Medicine Integration Task Force, and is now on the Nomination and Awards Council, the Education Committee, and the Membership Committee. He has been a regular speaker at CSAM conferences since 2006, serving on the conference planning committee since 2011, chairman for the Review Course in 2012, and vice chairman for the “State of the Art” course in 2018.
Mary Lieh-Lai, M.D.
Senior Vice President for Medical Accreditation
Accreditation Council for Graduate Medical Education (ACGME)
mliehlai@acgme.org

Dr. Lieh-Lai is the Senior Vice President, Medical Accreditation. She is also Professor of Pediatrics (Voluntary) at Wayne State University School of Medicine. She graduated from the University of Santo Tomas in the Philippines, and subsequently completed her pediatric residency and pediatric critical care medicine training at the Children's Hospital of Michigan/Wayne State University School of Medicine. She is board certified in pediatrics and pediatric critical care medicine. Following completion of her fellowship, Dr. Lieh-Lai was director of the ICU at the Georgetown University Medical Center, and she later returned to the Children's Hospital of Michigan, where she held various roles through the years, including Pediatric Residency Program Director and Vice Chair for Medical Education; Critical Care Medicine and Clinical Pharmacology Fellowship Program Director; ICU Director; Division Chief of Critical Care Medicine; and designated institutional official (DIO).

Dr. Lieh-Lai has been involved in medical education throughout her career. She instituted mock codes teaching-the-residents-how-to-teach series (Acute Care Resident Education Series), and monthly research workshops, and was instrumental in publishing the Pediatric Acute Care Handbook, which was written by pediatric residents under her mentorship, and which has been published in several editions and translated into Spanish and Turkish. Her mentorship also led to a second resident-driven book, Pocket Pediatrics. Dr. Lieh-Lai received teaching awards almost yearly for her efforts in teaching at the bedside and through the research workshops. She received the Wayne State University President Teaching Award; numerous College teaching awards, and awards from the Society of Critical Care Medicine, and was named Top Doctor several times. She also participated in numerous Operation Smile missions to at least 10 countries to provide care for children following cleft lip/palate repairs and offer educational activities.

On a national level, Dr. Lieh-Lai was a member of the Pediatrics Step II Committee for the National Board of Medical Examiners. She was a member of the ACGME Review Committee for Pediatrics and served as vice chair. She was a long-time newsletter editor for the American Academy of Pediatrics (AAP) Section on Critical Care, and is a member of the AAP’s Executive Committee. Dr. Lieh-Lai was a member of the PREP-ICU Editorial Board and was appointed to the ABP sub-board on critical care.

Dr. Lieh-Lai was funded by the National Institutes of Child Health and Human Development for 15 years as co-investigator or principal investigator as part of the Pediatric Pharmacology Research Network. She helped develop a mouse model of asthma and worked on nanotechnology for drug delivery. She headed multiple clinical trials related to the pharmacologic treatment of critically-ill children and medication errors in the ICU, with funding from Ronald McDonald Children Charities and Blue Cross/Blue Shield Network. She is the author of numerous peer-reviewed articles and book chapters.
Jerry Vasilias, Ph.D.

Executive Director
Review Committee for Internal Medicine
Accreditation Council for Graduate Medical Education (ACGME)

Jerry Vasilias, PhD, began his ACGME career in 1994, and has been the executive director for the Review Committee for Internal Medicine since May 2010.

Prior to this, he served as the executive director for the Review Committees for Family Medicine and Pediatrics. He previously worked in the ACGME Department of Field Activities as Associate Director, Field Staff Activities; and as a senior research associate at the ACGME.

Dr. Vasilias earned his PhD in applied social psychology from Loyola University Chicago, where he also earned his MA in applied social psychology, and his BA in psychology and philosophy.
William Hart works for the Accreditation Council for Graduate Medical Education (ACGME) as Associate Executive Director for the Review Committee for Internal Medicine and for the Osteopathic Principles Committee. He has been with the ACGME since 1998.
INTRODUCERS
listed in agenda order

Timothy Brennan, M.D., M.P.H.
Program Director, Addiction Institute at Mount Sinai West and Mount Sinai St. Luke’s Hospitals.
Program Director of the Fellowship in Addiction Medicine Program at the Icahn School of Medicine Mount Sinai
Vice President for Medical and Academic Affairs, The Addiction Medicine Foundation
Timothy.Brennan@mountsinai.org

Anna Lembke, M.D.
Associate Professor of Psychiatry and Behavioral Sciences, Stanford University Medical Center.
Program Director, Stanford Addiction Medicine Program
President, Addiction Medicine Fellowship Directors Association (AMFDA)
alembke@stanford.edu

Hoover Adger, Jr, M.D., M.P.H.
Professor of Pediatrics, Johns Hopkins University School of Medicine
Director of Adolescent Medicine in the Division of General Pediatrics and Adolescent Medicine
Director of both the Substance Abuse Assessment/Intervention Team at The Johns Hopkins Hospital Adolescent Program and the Johns Hopkins Substance Abuse Faculty Development Programs.
INTRODUCERS continued

Martha J. Wunsch, M.D.
Program Director, Addiction Medicine Fellowship at Kaiser Permanente Northern California
Martha.J.Wunsch@kp.org

Lon Robert Hays, M.D., M.B.A.
Program Director, University of Kentucky Addiction Medicine Fellowship
Professor, Dept of Psychiatry, University of Kentucky
lrhays@uky.edu

Paula Lum, M.D., M.P.H.
Program Director, UCSF Primary Care Addiction Medicine Fellowship
Professor of Clinical Medicine, University of California, (UCSF)
Paula.Lum@ucsf.edu
Randall Brown, M.D., Ph.D.
Program Director, University of Wisconsin Addiction Medicine Fellowship
Associate Professor, The University of Wisconsin Department of Family Medicine and Community Health
Randy.Brown@fammed.wisc.edu

Maireni Cruz Jimenez, M.D.
Fellow, University of Wisconsin Addiction Medicine Fellowship
Clinical Instructor, The University of Wisconsin Department of Family Medicine and Community Health
maireni.cruz@fammed.wisc.edu

Jeanette Tetrault, M.D.
Program Director, Yale University Addiction Medicine Fellowship
Associate Professor of Medicine (General Medicine), Yale School of Medicine
jeanette.tetrault@yale.edu
Scott Teitelbaum, M.D.

Program Director, University of Florida Addiction Medicine Fellowship
Vice Chair and Clinical Chief of the Addiction Medicine Division,
University of Florida, Gainesville
teitesa@ufl.edu

Sheila Specker, M.D.

Program Director, Minnesota Addiction Medicine Fellowship
Associate Professor, Department of Psychiatry, University of Minnesota
speck001@umn.edu

Andrew Danzo, B.A.

Director, Fellowship Development, The Addiction Medicine Foundation (TAMF)
University at Buffalo Dept. of Family Medicine
adanzo@addictionmedicinefoundation.org

Alexander Walley, M.D., M.Sc.

Program Director, Boston University Addiction Medicine Fellowship
Associate Professor of Medicine, Boston University School of Medicine
Awalley@bu.edu